---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-101817"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:29:47.227570+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem reports VS-7375 clears first two doses with tumor reduction in 4/5 evaluable patients

## Summary
- No DLTs at 400 mg QD and 600 mg QD; no nausea/vomiting/diarrhea > Grade 1.
- 4 of 5 efficacy-evaluable patients had tumor reduction and remain on treatment.
- Enrollment started for VS-7375 + cetuximab combo cohort in advanced solid tumors.
- Interim safety/efficacy update expected in first half 2026.
- Monotherapy dose escalation continues to 900 mg QD to select recommended Phase 2 dose.

## SEC filing metadata
- accession: 0001104659-25-101817
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/0001104659-25-101817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/tm2529362d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-101817
- JSON: https://secwatch.observer/filing/0001104659-25-101817.json
- Plain text: https://secwatch.observer/filing/0001104659-25-101817.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.